US6228879B1
(en)
*
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
US6518281B2
(en)
*
|
1995-08-29 |
2003-02-11 |
Celgene Corporation |
Immunotherapeutic agents
|
US5635517B1
(en)
*
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
HU228769B1
(en)
*
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
US7629360B2
(en)
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
WO2002064083A2
(en)
*
|
2000-11-30 |
2002-08-22 |
The Children's Medical Center Corporation |
Synthesis of 3-amino-thalidomide and its enantiomers
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
WO2003014315A2
(en)
*
|
2001-08-06 |
2003-02-20 |
The Children's Medical Center Corporation |
Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
|
US7498171B2
(en)
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
US7968569B2
(en)
*
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
NZ570777A
(en)
*
|
2002-05-17 |
2009-04-30 |
Celgene Corp |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
US20040087558A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
US20040091455A1
(en)
*
|
2002-10-31 |
2004-05-13 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
|
US8034831B2
(en)
*
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
MXPA05004780A
(es)
|
2002-11-06 |
2005-10-05 |
Celgene Corp |
Metodos y composiciones que usan farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de canceres y otros padecimientos.
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
BR0316256A
(pt)
*
|
2002-11-18 |
2005-10-04 |
Celgene Corp |
Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
|
NZ540547A
(en)
*
|
2002-11-18 |
2008-03-28 |
Celgene Corp |
Use of compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide for inhibiting TNF-alpha production
|
CH696542A5
(de)
*
|
2003-07-09 |
2007-07-31 |
Siegfried Ltd |
Verfahren zur Herstellung von substituierten 2,6-Dioxopiperidin-3-yl-Verbindungen.
|
GB0319069D0
(en)
*
|
2003-08-14 |
2003-09-17 |
Glaxo Group Ltd |
Therapeutically useful compounds
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US20080027113A1
(en)
*
|
2003-09-23 |
2008-01-31 |
Zeldis Jerome B |
Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
US20050100529A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
ZA200603718B
(en)
*
|
2003-11-06 |
2007-09-26 |
Celgene Corp |
Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
|
EP2065383A1
(en)
|
2003-11-19 |
2009-06-03 |
Signal Pharmaceuticals, Inc. |
Indazole compounds and methods of use thereof as protein kinase inhibitors
|
US20050143344A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
EP1737453A4
(en)
|
2004-03-22 |
2008-11-26 |
Celgene Corp |
METHOD FOR THE USE OF IMMUNOMODULATORY COMPOUNDS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF SKIN DISEASES OR DISORDERS
|
US20050222209A1
(en)
*
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
BRPI0418742A
(pt)
*
|
2004-04-14 |
2007-09-11 |
Celgene Corp |
métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
|
AU2005237490A1
(en)
*
|
2004-04-23 |
2005-11-10 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
|
US7405237B2
(en)
|
2004-07-28 |
2008-07-29 |
Celgene Corporation |
Isoindoline compounds and methods of their use
|
CA2579291C
(en)
*
|
2004-09-03 |
2011-11-29 |
Celgene Corporation |
Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
|
WO2006050057A2
(en)
*
|
2004-10-28 |
2006-05-11 |
Celgene Corporation |
Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
|
CN101102771A
(zh)
*
|
2004-11-23 |
2008-01-09 |
细胞基因公司 |
用免疫调节化合物治疗和控制中枢神经系统损伤的方法和组合物
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
AU2011221383B2
(en)
*
|
2005-06-30 |
2013-08-01 |
Celgene Corporation |
Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
|
WO2007005972A1
(en)
|
2005-06-30 |
2007-01-11 |
Celgene Corporation |
Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
|
KR20080026198A
(ko)
*
|
2005-06-30 |
2008-03-24 |
안트로제네시스 코포레이션 |
태반 유도된 콜라겐 바이오패브릭을 사용한 고막의 복원
|
US7928280B2
(en)
*
|
2005-07-13 |
2011-04-19 |
Anthrogenesis Corporation |
Treatment of leg ulcers using placenta derived collagen biofabric
|
EP1919365A2
(en)
*
|
2005-07-13 |
2008-05-14 |
Anthrogenesis Corporation |
Ocular plug formed from placenta derived collagen biofabric
|
DE602006020300D1
(de)
|
2005-09-01 |
2011-04-07 |
Celgene Corp |
Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
NZ597304A
(en)
*
|
2005-10-13 |
2013-06-28 |
Anthrogenesis Corp |
Immunomodulation using placental stem cells
|
CN101374941A
(zh)
*
|
2005-12-29 |
2009-02-25 |
人类起源公司 |
采集和保存胎盘干细胞的改良组合物及其使用方法
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
US20080064876A1
(en)
*
|
2006-05-16 |
2008-03-13 |
Muller George W |
Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
WO2008021391A1
(en)
*
|
2006-08-15 |
2008-02-21 |
Anthrogenesis Corporation |
Umbilical cord biomaterial for medical use
|
WO2008042441A1
(en)
*
|
2006-10-03 |
2008-04-10 |
Anthrogenesis Corporation |
Use of umbilical cord biomaterial for ocular surgery
|
US8071135B2
(en)
|
2006-10-04 |
2011-12-06 |
Anthrogenesis Corporation |
Placental tissue compositions
|
JP5769925B2
(ja)
|
2006-10-06 |
2015-08-26 |
アントフロゲネシス コーポレーション |
ヒト胎盤コラーゲン組成物、並びにそれらの製造方法及び使用方法
|
CN101657206B
(zh)
*
|
2007-02-12 |
2013-07-03 |
人类起源公司 |
利用胎盘干细胞治疗炎性疾病
|
CN101688177A
(zh)
*
|
2007-02-12 |
2010-03-31 |
人类起源公司 |
来自贴壁胎盘干细胞的肝细胞和软骨细胞;以及cd34+、cd45-胎盘干细胞富集的细胞群
|
US7893045B2
(en)
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
WO2009039635A1
(en)
*
|
2007-09-24 |
2009-04-02 |
Painceptor Pharma Corporation |
Methods of modulating neurotrophin-mediated activity
|
CN101878034B
(zh)
|
2007-09-28 |
2013-11-20 |
细胞基因细胞疗法公司 |
使用人胎盘灌洗液和人来自胎盘的中间体自然杀伤细胞的肿瘤抑制
|
WO2009058394A1
(en)
*
|
2007-11-01 |
2009-05-07 |
Celgene Corporation |
Cytidine analogs for treatment of myelodysplastic syndromes
|
US7964354B2
(en)
*
|
2007-12-20 |
2011-06-21 |
Celgene Corporation |
Use of micro-RNA as a biomarker of immunomodulatory drug activity
|
US20090232796A1
(en)
*
|
2008-02-20 |
2009-09-17 |
Corral Laura G |
Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
|
NZ595440A
(en)
|
2009-03-25 |
2014-05-30 |
Anthrogenesis Corp |
Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
|
EP2436387B1
(en)
|
2009-05-25 |
2018-07-25 |
Celgene Corporation |
Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
|
CN101580501B
(zh)
*
|
2009-06-01 |
2011-03-09 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
|
EP2851070A1
(en)
|
2010-01-05 |
2015-03-25 |
Celgene Corporation |
A combination of lenalidomide and artesunate/artemisone for treating cancer
|
CA2794096A1
(en)
|
2010-04-07 |
2011-10-13 |
Celgene Corporation |
Methods for treating respiratory viral infection
|
MX2013012083A
(es)
|
2011-04-18 |
2014-04-16 |
Celgene Corp |
Biomarcadores para el tratamiento de mieloma multiple.
|
JP6016892B2
(ja)
|
2011-04-29 |
2016-10-26 |
セルジーン コーポレイション |
セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法
|
US10335482B2
(en)
|
2012-06-06 |
2019-07-02 |
Bionor Immuno As |
Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer
|
WO2014004990A2
(en)
|
2012-06-29 |
2014-01-03 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
EP3622960A1
(en)
|
2013-02-05 |
2020-03-18 |
Celularity, Inc. |
Natural killer cells from placenta
|
WO2014172429A1
(en)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
|
CN103232380A
(zh)
*
|
2013-05-08 |
2013-08-07 |
中国药科大学 |
一种泊马度胺关键中间体的制备方法
|
WO2015007337A1
(en)
|
2013-07-19 |
2015-01-22 |
Bionor Immuno As |
Method for the vaccination against hiv
|
ES2843973T3
(es)
|
2014-06-27 |
2021-07-21 |
Celgene Corp |
Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3
|
HUE061382T2
(hu)
|
2014-08-22 |
2023-06-28 |
Celgene Corp |
Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva
|
CN105440013B
(zh)
*
|
2014-08-29 |
2018-10-09 |
杭州和泽医药科技有限公司 |
一种泊马度胺的制备方法
|
EP3313818B1
(en)
|
2015-06-26 |
2023-11-08 |
Celgene Corporation |
Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
CN107365295B
(zh)
*
|
2016-05-11 |
2020-07-07 |
常州制药厂有限公司 |
一种泊马度胺合成工艺的改进方法
|
CN106432045B
(zh)
*
|
2016-06-29 |
2018-12-18 |
深圳海王医药科技研究院有限公司 |
一种泊马度胺杂质的合成方法
|
BR112019011025A2
(pt)
|
2016-12-03 |
2019-10-08 |
Juno Therapeutics Inc |
métodos para modulação de células t car
|
SG11201910143TA
(en)
|
2017-05-01 |
2019-11-28 |
Juno Therapeutics Inc |
Combination of a cell therapy and an immunomodulatory compound
|
WO2018223101A1
(en)
|
2017-06-02 |
2018-12-06 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
EP3644721A1
(en)
|
2017-06-29 |
2020-05-06 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
US20200246393A1
(en)
|
2017-09-28 |
2020-08-06 |
Celularity, Inc. |
Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
|
BR112020008323A2
(pt)
|
2017-11-01 |
2020-11-03 |
Juno Therapeutics Inc |
anticorpos e receptores de antígenos quiméricos específicos para antígeno de maturação de células b
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
US12006356B2
(en)
|
2017-12-15 |
2024-06-11 |
Juno Therapeutics, Inc. |
Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
|
US11401336B2
(en)
|
2018-02-21 |
2022-08-02 |
Celgene Corporation |
BCMA-binding antibodies and uses thereof
|
SG11202104411VA
(en)
|
2018-11-08 |
2021-05-28 |
Juno Therapeutics Inc |
Methods and combinations for treatment and t cell modulation
|
US20220008465A1
(en)
|
2018-11-16 |
2022-01-13 |
Juno Therapeutics, Inc. |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
SG11202105502RA
(en)
|
2018-11-30 |
2021-06-29 |
Juno Therapeutics Inc |
Methods for treatment using adoptive cell therapy
|
PE20212198A1
(es)
|
2019-01-29 |
2021-11-16 |
Juno Therapeutics Inc |
Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1)
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|